Literature DB >> 32808680

A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Christopher Pleyer1, Xin Tian2, Shakuntala Rampertaap3, Rui Mu1, Susan Soto1, Jeanine Superata1, Erika Gaglione1, Clare Sun1, Jennifer Lotter1, Maryalice Stetler-Stevenson4, Constance M Yuan4, Irina Maric3, Stefania Pittaluga4, Sergio Rosenzweig3, Thomas Fleisher3, Adrian Wiestner1, Inhye E Ahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32808680      PMCID： PMC8932338          DOI： 10.1002/ajh.25968

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


× No keyword cloud information.
  5 in total

1.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

3.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps
Journal:  Blood       Date:  2018-03-14       Impact factor: 22.113

4.  Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.

Authors:  Paolo Strati; Ellen J Schlette; Luisa M Solis Soto; Daniela E Duenas; Mariela Sivina; Ekaterina Kim; Michael J Keating; William G Wierda; Alessandra Ferrajoli; Hagop Kantarjian; Zeev Estrov; Nitin Jain; Philip A Thompson; Ignacio I Wistuba; Jan A Burger
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

5.  Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Authors:  Inhye E Ahn; Mohammed Z H Farooqui; Xin Tian; Janet Valdez; Clare Sun; Susan Soto; Jennifer Lotter; Stephanie Housel; Maryalice Stetler-Stevenson; Constance M Yuan; Irina Maric; Katherine R Calvo; Pia Nierman; Thomas E Hughes; Nakhle S Saba; Gerald E Marti; Stefania Pittaluga; Sarah E M Herman; Carsten U Niemann; Lone B Pedersen; Christian H Geisler; Richard Childs; Georg Aue; Adrian Wiestner
Journal:  Blood       Date:  2018-02-26       Impact factor: 22.113
  5 in total
  2 in total

Review 1.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

Review 2.  Targeting Bruton's Tyrosine Kinase in CLL.

Authors:  Inhye E Ahn; Jennifer R Brown
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.